Intravaginal Home-Use Device Cleared for Stress Urinary Incontinence
Flyte is an in-home treatment designed to strengthen and treat weakened pelvic floor muscles.
Overactive Bladder/Enuresis
Vesicare LS Approved for Neurogenic Detrusor Overactivity
The FDA has approved Vesicare LS (solifenacin succinate; Astellas Pharma) oral suspension for the treatment of neurogenic detrusor overactivity (NDO) in pediatric patients 2 years of age and older.
Next-Gen Rechargeable Neurostimulator Implant Approved for Urinary, Bowel Dysfunction
The FDA has approved a new version of Axonics Modulation’s rechargeable implantable sacral neurostimulator (r-SNM) system that allows patients to decrease the frequency of charging to once a month.
Anticholinergic Meds for Overactive Bladder May Up Dementia Risk
Among patients with overactive bladder (OAB), anticholinergic medication use appears to be associated with an increased risk of new onset dementia when compared with beta-3 agonist use, according to the findings of a retrospective population-based cohort study.
Vibegron Under Review for Overactive Bladder Treatment
The FDA has accepted for review the New Drug Application for vibegron (Urovant Sciences) for the treatment of patients with overactive bladder with symptoms of urge urinary incontinence, urgency, and urinary frequency.
NDA Submitted for Vibegron for Overactive Bladder Treatment
Urovant Sciences has submitted a New Drug Application (NDA) to the Food and Drug Administration (FDA) for vibegron, a beta-3 adrenergic agonist, for the treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency, and urinary frequency. The NDA submission includes data from an extensive clinical development program involving over 4000 patients with…
Sacral Neuromodulation Device Approved for OAB, Urinary Retention
Axonics Modulation Technologies has received premarket approval from the Food and Drug Administration (FDA) for Axonics r-SNM System, an implantable sacral neuromodulation device (SMN), for the treatment of overactive bladder (OAB) and urinary retention.
OTC Urethral Support Device Now Available to Treat Stress Urinary Incontinence
An over-the-counter device to treat stress urinary incontinence (SUI) in women has been made available by Rinovum Women’s Health.
Solabegron Meets Primary Endpoint in Overactive Bladder Study
Velicept Therapeutics announced that solabegron met the primary endpoint in the phase 2b VEL-2002 study that evaluated patients with overactive bladder (OAB).
Vibegron Cuts Daily Urge Urinary Incontinence Episodes, Micturitions in OAB Study
Urovant Sciences announced topline data from the phase 3 EMPOWUR trial which evaluated vibegron in adult patients with symptoms of overactive bladder.
